You have free access to this content

Hepatology

Cover image for Hepatology

July 2009

Volume 50, Issue 1

Pages 1–331

  1. Comments from the Editors

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
  2. Editorial

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Alternative pathway therapy for hyperammonemia in liver failure (pages 3–5)

      Fin Stolze Larsen and Julia Wendon

      Version of Record online: 22 APR 2009 | DOI: 10.1002/hep.23037

  3. Viral Hepatitis

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development (pages 6–16)

      Leen Delang, Jan Paeshuyse, Inge Vliegen, Pieter Leyssen, Susan Obeid, David Durantel, Fabien Zoulim, Anne Op de Beeck and Johan Neyts

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22916

    2. You have free access to this content
      PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression (pages 17–24)

      Patrick Labonté, Syntia Begley, Carl Guévin, Marie-Claude Asselin, Nasha Nassoury, Gaétan Mayer, Annik Prat and Nabil G. Seidah

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22911

    3. You have free access to this content
      Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A (pages 25–33)

      Zhe Liu, John M. Robida, Sreedhar Chinnaswamy, Guanghui Yi, Jason M. Robotham, Heather B. Nelson, Andre Irsigler, C. Cheng Kao and Hengli Tang

      Version of Record online: 6 APR 2009 | DOI: 10.1002/hep.22987

    4. You have free access to this content
      Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells (pages 34–45)

      Shyam Kottilil, Michael Y. Yan, Kristin N. Reitano, Xiaozhen Zhang, Richard Lempicki, Gregg Roby, Marybeth Daucher, Jun Yang, Karoll J. Cortez, Marc Ghany, Michael A. Polis and Anthony S. Fauci

      Version of Record online: 6 MAY 2009 | DOI: 10.1002/hep.23055

    5. You have free access to this content
      Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference (pages 46–55)

      Pantxika Bellecave, Jérôme Gouttenoire, Markus Gajer, Volker Brass, George Koutsoudakis, Hubert E. Blum, Ralf Bartenschlager, Michael Nassal and Darius Moradpour

      Version of Record online: 16 MAR 2009 | DOI: 10.1002/hep.22951

  4. Steatohepatitis/Metabolic Liver Disease

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine (pages 56–67)

      Lydia Lee, Mouhamad Alloosh, Romil Saxena, William Van Alstine, Bruce A. Watkins, James E. Klaunig, Michael Sturek and Naga Chalasani

      Version of Record online: 11 FEB 2009 | DOI: 10.1002/hep.22904

    2. You have free access to this content
      Independent effects of physical activity in patients with nonalcoholic fatty liver disease (pages 68–76)

      Alexis St. George, Adrian Bauman, Amanda Johnston, Geoffrey Farrell, Tien Chey and Jacob George

      Version of Record online: 6 MAR 2009 | DOI: 10.1002/hep.22940

    3. You have free access to this content
      Apolipoprotein B100 acts as a molecular link between lipid-induced endoplasmic reticulum stress and hepatic insulin resistance (pages 77–84)

      Qiaozhu Su, Julie Tsai, Elaine Xu, Wei Qiu, Erika Bereczki, Miklos Santha and Khosrow Adeli

      Version of Record online: 11 MAY 2009 | DOI: 10.1002/hep.22960

    4. You have free access to this content
      Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice (pages 85–93)

      Hongmei Zhao, Malgorzata Przybylska, I-Huan Wu, Jinhua Zhang, Panagiotis Maniatis, Joshua Pacheco, Peter Piepenhagen, Diane Copeland, Cynthia Arbeeny, James A. Shayman, Johannes M. Aerts, Canwen Jiang, Seng H. Cheng and Nelson S. Yew

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22970

    5. You have free access to this content
      HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity (pages 94–101)

      Lyle C. Gurrin, Nadine A. Bertalli, Gregory W. Dalton, Nicholas J. Osborne, Clare C. Constantine, Christine E. McLaren, Dallas R. English, Dorota M. Gertig, Martin B. Delatycki, Amanda J. Nicoll, Melissa C. Southey, John L. Hopper, Graham G. Giles, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Katrina J. Allen and HealthIron Study Investigators

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22972

  5. Hepatobiliary Malignancies

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma (pages 102–112)

      Marco Breinig, Eloisi Caldas-Lopes, Benjamin Goeppert, Mona Malz, Ralf Rieker, Frank Bergmann, Peter Schirmacher, Matthias Mayer, Gabriela Chiosis and Michael André Kern

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22912

    2. You have free access to this content
      MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells (pages 113–121)

      Teng Xu, Ying Zhu, Yujuan Xiong, Yi-Yuan Ge, Jing-Ping Yun and Shi-Mei Zhuang

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22919

    3. You have free access to this content
      Chromodomain helicase/adenosine triphosphatase DNA binding protein 1–like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival (pages 122–129)

      Leilei Chen, Liang Hu, Tim Hon Man Chan, George Sai-Wah Tsao, Dan Xie, Ke-Ke Huo, Li Fu, Stephanie Ma, Bo-Jian Zheng and Xin-Yuan Guan

      Version of Record online: 3 MAR 2009 | DOI: 10.1002/hep.22933

  6. Autoimmune, Cholestatic and Biliary Disease

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells (pages 130–142)

      Maria Serena Longhi, Ragai R. Mitry, Marianne Samyn, Astrid Scalori, Munther J. Hussain, Alberto Quaglia, Giorgina Mieli-Vergani, Yun Ma and Diego Vergani

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22914

    2. You have free access to this content
      Bile salt–phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent (pages 143–154)

      Walee Chamulitrat, Jürgen Burhenne, Tobias Rehlen, Anita Pathil and Wolfgang Stremmel

      Version of Record online: 16 MAR 2009 | DOI: 10.1002/hep.22955

  7. Liver Failure/Cirrhosis/Portal Hypertension

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats (pages 155–164)

      Nathan A. Davies, Gavin Wright, Lars M. Ytrebø, Vanessa Stadlbauer, Ole-Martin Fuskevåg, Claudia Zwingmann, D. Ceri Davies, Abeba Habtesion, Stephen J. Hodges and Rajiv Jalan

      Version of Record online: 9 FEB 2009 | DOI: 10.1002/hep.22897

    2. You have free access to this content
      L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure (pages 165–174)

      Lars Marius Ytrebø, Rune Gangsøy Kristiansen, Hanne Mæhre, Ole Martin Fuskevåg, Trine Kalstad, Arthur Revhaug, María Jover Cobos, Rajiv Jalan and Christopher F. Rose

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22917

    3. You have free access to this content
    4. You have free access to this content
      CCR2 promotes hepatic fibrosis in mice (pages 185–197)

      Ekihiro Seki, Samuele de Minicis, Sayaka Inokuchi, Kojiro Taura, Katsumi Miyai, Nico van Rooijen, Robert F. Schwabe and David A. Brenner

      Version of Record online: 16 MAR 2009 | DOI: 10.1002/hep.22952

  8. Liver Injury/Regeneration

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Toll-like receptor 3 signaling attenuates liver regeneration (pages 198–206)

      Elina Zorde-Khvalevsky, Rinat Abramovitch, Hila Barash, Irit Spivak-Pohis, Ludmila Rivkin, Jacob Rachmilewitz, Eithan Galun and Hilla Giladi

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22973

    2. You have free access to this content
      p21 is required for dextrose-mediated inhibition of mouse liver regeneration (pages 207–215)

      Alexander Weymann, Eric Hartman, Vered Gazit, Connie Wang, Martin Glauber, Yumirle Turmelle and David A. Rudnick

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22979

    3. You have free access to this content
      S6K1 deficiency protects against apoptosis in hepatocytes (pages 216–229)

      Águeda González-Rodriguez, Javier Alba, Valeri Zimmerman, Sara C. Kozma and Ángela M. Valverde

      Version of Record online: 18 FEB 2009 | DOI: 10.1002/hep.22915

  9. Liver Biology/Pathobiology

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      The etiology of liver damage imparts cytokines transforming growth factor β1 or interleukin-13 as driving forces in fibrogenesis (pages 230–243)

      Hong-Lei Weng, Yan Liu, Jia-Lin Chen, Tong Huang, Li-Jun Xu, Patricio Godoy, Jun-Hua Hu, Cheng Zhou, Felix Stickel, Alexander Marx, Rainer M. Bohle, Vincent Zimmer, Frank Lammert, Sebastian Mueller, Michelle Gigou, Didier Samuel, Peter R. Mertens, Manfred V. Singer, Helmut K. Seitz and Steven Dooley

      Version of Record online: 3 MAR 2009 | DOI: 10.1002/hep.22934

    2. You have free access to this content
      Diferentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation (pages 244–252)

      Mario Strazzabosco, Romina Fiorotto, Saida Melero, Shannon Glaser, Heather Francis, Carlo Spirli and Gianfranco Alpini

      Version of Record online: 3 MAR 2009 | DOI: 10.1002/hep.22926

    3. You have free access to this content
      Hypoxia-inducible factor 1α is up-regulated by oncostatin M and participates in oncostatin M signaling (pages 253–260)

      Stefan Vollmer, Valérie Kappler, Jakub Kaczor, Daniela Flügel, Catherine Rolvering, Nobuyuki Kato, Thomas Kietzmann, Iris Behrmann and Claude Haan

      Version of Record online: 3 MAR 2009 | DOI: 10.1002/hep.22928

    4. You have free access to this content
      Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis (pages 261–274)

      Karlin Raja Karlmark, Ralf Weiskirchen, Henning W. Zimmermann, Nikolaus Gassler, Florent Ginhoux, Christian Weber, Miriam Merad, Tom Luedde, Christian Trautwein and Frank Tacke

      Version of Record online: 16 MAR 2009 | DOI: 10.1002/hep.22950

    5. You have free access to this content
      Single nucleotide polymorphism–mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency (pages 275–281)

      Shujuan Pan, Lu Huang, John McPherson, Donna Muzny, Farshid Rouhani, Mark Brantly, Richard Gibbs and Richard N. Sifers

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22974

    6. You have free access to this content
      Protein or amino acid deprivation differentially regulates the hepatic forkhead box protein A (FOXA) genes through an activating transcription factor-4–independent pathway (pages 282–290)

      Nan Su, Michelle M. Thiaville, Keytam Awad, Altin Gjymishka, Jason O. Brant, Thomas P. Yang and Michael S. Kilberg

      Version of Record online: 19 MAR 2009 | DOI: 10.1002/hep.22971

  10. AASLD Practice Guidelines

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Primary biliary cirrhosis (pages 291–308)

      Keith D. Lindor, M. Eric Gershwin, Raoul Poupon, Marshall Kaplan, Nora V. Bergasa and E. Jenny Heathcote

      Version of Record online: 11 FEB 2009 | DOI: 10.1002/hep.22906

  11. AASLD Public Policy

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
  12. Image of the Month

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Albinism, cyclic neutropenia, and ceroid pigment in the liver (pages 314–315)

      Julien Calderaro and Elie Serge Zafrani

      Version of Record online: 20 MAY 2009 | DOI: 10.1002/hep.23080

  13. Hepatology Elsewhere

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
  14. Correspondence

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
    2. You have free access to this content
      Reply: (page 320)

      Kinji Asahina and Hidekazu Tsukamoto

      Version of Record online: 7 APR 2009 | DOI: 10.1002/hep.23013

    3. You have free access to this content
      Orlistat for overweight subjects with nonalcoholic steatohepatitis (page 321)

      Joanna K. Dowman, Deborah Stocken, Jeremy W. Tomlinson and Philip Newsome

      Version of Record online: 2 JUN 2009 | DOI: 10.1002/hep.23079

    4. You have free access to this content
      Reply: (pages 321–322)

      Stephen Harrison, Elizabeth Brunt and Brent Neuschwander-Tetri

      Version of Record online: 2 JUN 2009 | DOI: 10.1002/hep.23017

    5. You have free access to this content
      Diagnosis, management, and treatment of hepatitis C (page 322)

      Claudio Puoti, Riccardo Guarisco, Lia Bellis and Lucia Spilabotti

      Version of Record online: 13 APR 2009 | DOI: 10.1002/hep.23015

    6. You have free access to this content
    7. You have free access to this content
    8. You have free access to this content
      Reply: (pages 324–325)

      Leonard B. Seeff, Marc G. Ghany, Doris B. Strader and David L. Thomas

      Version of Record online: 20 MAY 2009 | DOI: 10.1002/hep.23084

    9. You have free access to this content
    10. You have free access to this content
      Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas (page 326)

      Marc-Oliver Riener, Frank Stenner, Heike Liewen, Claus Hellerbrand, Marcus Bahra and Glen Kristiansen

      Version of Record online: 1 MAY 2009 | DOI: 10.1002/hep.23053

    11. You have free access to this content
      Adipocytokine levels in nonalcoholic fatty liver disease (pages 326–327)

      Teoman Dogru, Cemal Nuri Ercin, Serkan Tapan, Murat Kantarcioglu, Muammer Kara and Sait Bagci

      Version of Record online: 17 APR 2009 | DOI: 10.1002/hep.23029

    12. You have free access to this content
      Reply: (pages 327–328)

      David van der Poorten, Kerry-Lee Milner, Donald J. Chisholm and Jacob George

      Version of Record online: 20 MAY 2009 | DOI: 10.1002/hep.23088

    13. You have free access to this content
    14. You have free access to this content
      Reply: (page 329)

      Anna M. G. Cali and Sonia Caprio

      Version of Record online: 6 MAY 2009 | DOI: 10.1002/hep.23056

    15. You have free access to this content
    16. You have free access to this content
      Interleukin-17–targeted treatment of alcoholic liver disease (pages 329–330)

      Enzo Emanuele and Marco Bertona

      Version of Record online: 7 APR 2009 | DOI: 10.1002/hep.22901

  15. Corrections

    1. Top of page
    2. Comments from the Editors
    3. Editorial
    4. Viral Hepatitis
    5. Steatohepatitis/Metabolic Liver Disease
    6. Hepatobiliary Malignancies
    7. Autoimmune, Cholestatic and Biliary Disease
    8. Liver Failure/Cirrhosis/Portal Hypertension
    9. Liver Injury/Regeneration
    10. Liver Biology/Pathobiology
    11. AASLD Practice Guidelines
    12. AASLD Public Policy
    13. Image of the Month
    14. Hepatology Elsewhere
    15. Correspondence
    16. Corrections
    1. You have free access to this content
      Corrections (page 331)

      Version of Record online: 24 JUN 2009 | DOI: 10.1002/hep.23081

    2. You have free access to this content
      Corrections (page 331)

      Version of Record online: 24 JUN 2009 | DOI: 10.1002/hep.23078

SEARCH

SEARCH BY CITATION